ISTAART Professional Interest Areas (PIA) Events

PIA Day at AAIC: Saturday, July 15
PIA Business Meetings: Saturday, July 15 through Wednesday, July 19
ExCeL London, Platinum Suites 1-4

 

Null

 

Join the Professional Interest Areas (PIAs) of the Alzheimer's Association International Society to Advance Alzheimer's Research and Treatment (ISTAART) on Saturday, July 15 for PIA Day at AAIC. PIA Day hosts a full day of targeted scientific sessions organized by PIA leaders. Members may attend any of the PIA Day sessions or business meetings regardless of PIA membership.

Many of the PIAs will also host their annual business meeting on PIA Day, although some business meetings will take place throughout the week of AAIC. PIA business meetings are an opportunity to receive updates on activities, engage in critical conversations about issues affecting the field, network with peers from across the world and determine objectives for the upcoming year.

Daily Schedule

Preconferences (organized by PIAs; open to members and non-members), followed by Business Meetings

Neuroimaging PIA
Alzheimer's Imaging Consortium Preconference (registration fee required; open to members and non-members)
ExCeL London, Room S10-C
8 a.m. – 5:30 p.m.

Neuroimaging PIA Business Meeting
Crowne Plaza Hotel, Room: Victoria*
*Note: different location from AIC.

6 – 7 p.m.


Technology PIA
Technology & Dementia Preconference (registration fee required; open to members and non-members)
Grange Tower Bridge Hotel, Room: Trinity Suite
9 a.m. – 4 p.m.

Technology PIA Business Meeting:
Grange Tower Bridge Hotel, Room: Trinity Suite
4:15 – 5:15 p.m.

PIA Day Events

7:30 – 10 a.m.

Clinical Trials Advancement and Methods PIA
ExCeL London (Platinum Suite 1)
Scientific Session: 7:30 – 9 a.m. | Business Meeting: 9 – 10 a.m.

This PIA's core theme is "clinical trials advancement." We examine current trials methods, innovative pharmacological and non-pharmacological clinical trials and their designs, provide members an opportunity to discuss new and ongoing trials, exchange ideas on how to improve trials, collaborate and, finally, assist streamlining the publication process of manuscripts focusing on trial designs. The PIA's theme is not limited to statistical issues, but more broadly to the overall methods and strategies to improve trial designs. The theme of our PIA Day scientific session is, "New Perspectives in Alzheimer’s Disease (AD) Clinical Trial Approaches." Invited presenters from diverse backgrounds will discuss why AD Phase III trials keep failing, what we can do to improve AD clinical trials and their views and new perspectives in AD clinical trials. Each presenter has 12-15 minutes for presentations and 2-5 minutes for a question-and-answer period. Our 90-minute scientific session will be followed by our annual business meeting, which includes updates of European Prevention of AD Consortium (EPAD) from Dr. Craig Ritchie and an introduction of International Research Network on Dementia Prevention (IRNDP) initiatives by Dr. Kaarin Anstey. The business meeting will also provide excellent networking opportunities.

Agenda

7:30 - 7:35 a.m. Hiroko Dodge, Opening Remarks, Oregon Health & Science University and the University of Michigan, United States

7:35 - 7:52 a.m. Howard Feldman, Re-approaching Proof Of Concept: Emerging Opportunities, University of California, San Diego, United States

7:52 - 8:09 a.m. Michael Lutz, Application Of Molecular Understanding Of AD To Clinical Development: Lessons From Cancer Research, Duke University, United States

8:09 - 8:26 a.m. Todd Golde, Disruptive Approaches To Development And Testing Of New AD Therapies, University of Florida, United States

8:26 - 8:43 a.m. Lon Schneider, Phase 3 Trials Have Failed Because Their Phase 2 Trials Were Uninformative: The Need To Learn Some Stuff, Keck School of Medicine of the University of Southern California, United States

8:43 – 8:53 a.m. Craig Ritchie, What’s New And Exciting From The European Prevention Of Alzheimer’s Dementia Consortium (EPAD), University of Edinburgh, United Kingdom

8:53 – 9 a.m. Kaarin Anstey, Introduction Of IRNDP Initiative, Australian National University, Australia



Immunity and Neurodegeneration PIA
ExCeL London (Platinum Suite 2)
Scientific Session: 7:30 – 9 a.m. | Business Meeting: 9 – 10 a.m.

Reactive glial cells play a critical role in the development and progression of Alzheimer's disease, vascular cognitive impairment and other neurodegenerative processes. In this PIA Day session, we will explore exciting new roles for astrocytes and microglia in neuroinflammation and Alzheimer's disease. The Immunity and Neurodegeneration PIA is a unique working group of basic, translational and clinical researchers interested in mechanisms controlling neurodegeneration mediated by cellular or innate immunity and/or glial activation, developed for the purpose of stimulating interdisciplinary research, identifying knowledge gaps on issues critical to the field and developing consensus, collegiality and career advancement among investigators in the field. Please join us for a sensational scientific program, followed by a business meeting highlighting future goals and networking opportunities.

Agenda

7:30 - 7:35 a.m. Marcia Gordon, Welcome And Opening Remarks, University of South Florida, United States

7:35 - 7:45 a.m. Brittani Price, Astrocytic End-foot Disruption As A Key Mediator Of Vascular Cognitive Impairment And Dementia (VCID), University of Kentucky, United States

7:45 - 8 a.m. Carole Escartin, Insights Into Roles Of Reactive Astrocytes In AD Through Selective Modulation In Mouse Models, MIRCen CNRS-CEA UMR9199, France

8 - 8:30 a.m. Marina Lynch, How Does The Metabolic Signature Of Microglia From App/Ps1 Mice Impact On Inflammation?, Trinity College, Ireland

8:30 - 9 a.m. Heneka, Micheal, Microglia Fate And Disease Progression In Alzheimer's Disease, University of Bonn, Germany


8 – 10:30 a.m.

Nutrition, Metabolism and Dementia PIA
ExCeL London (Platinum Suite 3)
Business Meeting: 8 – 9 a.m. | Scientific Session: 9 – 10:30 a.m.

This year, presentations will take the form of data blitz. Each presenter will present for 3-4 minutes with an additional 1-2 minutes for questions at the end of each presentation (overall not more than 5 minutes for each presentation). We therefore recommend 5 slides per presentation (Title, Authors, Introduction, Methods, Results, Conclusions). We will have additional 5-10 minutes at the end for additional discussion.

Agenda

9:00 - 9:05 a.m. Nikos Scarmeas, Opening Remarks, Columbia University, United States; The National and Kapodistrian University of Athens, Greece

9:05 - 9:10 a.m. Josiane Budni, Involvement Of Neuroinflammation In The Memory Of Adult And Old Offspring Of Wistar Rats With Folic Acid Deficiency Or Supplementation During The Pregnancy, UNESC, Brazil

9:10 - 9:15 a.m. Frederic Calon, Effects Of Specific Nutrients On Cognition And AD Neuropathology: The Case Of Branched-chain Amino Acids (BCAA), UNESC, Brazil

9:15 - 9:20 a.m. Sally Frautschy, Dietary N-6 Linoleic Acid (High La Diet) And Its N-6 Metabolite Dpan-6 Attenuate Aberrant Neuroinflammation And Promote Amyloid-β Clearance, University of California, Los Angeles, United States

9:20 - 9:25 a.m. Ondine van de Rest, Serum Long-chain N-3 Fatty Acid Levels Are Associated With Presynaptic Proteins In The Human Brain, Wageningen University, United States

9:25 - 9:30 a.m. Joe Webb, Alzheimer's and Dementia: The Neuropeptide YY Story, Iowa State University, United States

9:30 - 9:35 a.m. Auriel Willette, SIRT1 Polymorphisms Modify Regional Grey Matter, Cognition, and White Matter Integrity, Iowa State University, United States

9:35 - 9:40 a.m. Edward Hill, Family History Of Dementia Impacts Dietary Inflammatory Index Scores In Healthy Ageing Australian Women – A Case Of Reverse Causality?, University of Melbourne, Australia

9:40 - 9:45 a.m. Diane Hosking, The MIND Diet Is Associated With Reduced Incidence Of 12-year Cognitive Impairment In An Australian Setting, The Australian National University, Australia

9:45 - 9:50 a.m. Claire McEvoy, Neuroprotective Diets Are Associated With Better Cognitive Performance In Older U.S. Adults: The Health And Retirement Study, University of California, San Francisco, United States

9:50 - 9:55 a.m. Debora Melo van Lent, Prospective Associations Between Vitamins And Metabolites, And Overall Dementia In The Oldest Old, German Center for Neurodegenerative Diseases, Germany

9:55 - 10:00 a.m. Cécilia Samieri, Modeling Approaches From Big Data As A Novel Way To Explore Dietary Patterns And Dementia Risk, University of Bordeaux, France

10:00 - 10:05 a.m. Gary Gibson, Glucose Metabolism As A Therapeutic Target In Alzheimer’s Disease, Burke Medical Research Institute, United States

10:05 - 10:10 a.m. Tobias Hartmann, Multi-nutrient Intervention In Prodromal Alzheimer's Disease: Rationale Based On Preclinical Studies And Results From The Double-blind Randomized Controlled Lipididiet Study Weill Cornell Medicine, Burke Medical Research Institute, United States; Medical Faculty, Saarland University, Germany

10:10 - 10:15 a.m. Richard Ronan Murphy, Design Of A Phase-ii Study To Assess The Safety, Tolerability, And Effects Of AT-001, A Yeast Selenium Compound, On CSF Aβ42 And Serum Prostaglandins In Non-demented Subjects At Risk For Cognitive Decline, Deutsches Institut für Demenz Prävention (DIDP), Medical Faculty, University of Kentucky, United States

10:15 - 10:20 a.m. Roni Lotan, Dietary Reduction Of Advanced Glycation End Products To Prevent Cognitive Decline In High-risk Diabetics - A Pilot Randomized Trial, The Hebrew University, Israel

10:20 - 10:30 a.m. Nikos Scarmeas, Closing Remarks, Columbia University, United States; The National and Kapodistrian University of Athens, Greece


Neuropsychiatric Syndromes PIA
ExCeL London (Platinum Suite 4)
Business Meeting: 8 – 9 a.m. | Scientific Session: 9 – 10:30 a.m.

Neuropsychiatric Syndromes (NPS) in Neurodegenerative Disease are widely acknowledged as a major public-health priority area in the field of neurodegenerative disease. Experts recognize the universal prevalence of these symptoms in Alzheimer's and related conditions, the significant added disability for patients and caregivers associated with NPS and the relative scarcity of effective treatments for NPS. The NPS PIA focuses on defining clinical entities that will serve as targets for research and treatment development in later years. Sub-groups related to specific NPS in Alzheimer's disease, for example apathy, agitation and psychosis, as well as a group working on mild behavioral impairment (MBI) work to develop a series of next steps to meet the PIA's overall objective. The NPS PIA Day session will feature various presentations, followed by a minute madness session highlighting NPS-related posters.

Agenda

9:00 - 9:04 a.m. Joanne Bell, Opening Remarks, Inc Research, United States

9:04 - 9:11 a.m. Paul Rosenberg, Longitudinal Cache County Data, Johns Hopkins School of Medicine, United States

9:11 - 9:18 a.m. Nancy Donovan, Longitudinal Associations Of Amyloidosis And Nps/Depression In Cognitively Normal Older People, Centre for Alzheimer's Research and Treatment, United States

9:18 - 9:25 a.m. Karra Harrington, Longitudinal Data From The AIBL Study, Australia; University of Melbourne, Australia

9:25 - 9:32 a.m. Jeannie-Marie S. Leoutsakos, Using Course of NPS among Pre-clinical NACC Participants to Predict MCI and Dementia, Johns Hopkins University, United States

9:32 - 9:39 a.m. Larry Ereshefsky, Neurocircuitry Strategies From Psychiatry, Follow The Molecule LLC, United States

9:39 - 9:46 a.m. David Miller, Drug Development And Treatment Of Apathy, Bracket, United States

9:46 - 9:53 a.m. Gad Marshall, Examining The Neurocircuitry Of Apathy And Markers Of Neurodegeneration In Early Alzheimer's Disease, Harvard Medical School, United States

9:53 - 10 a.m. Paul Rosenberg, Pilot Trial Of Dronabinol Adjunctive Treatment Of Agitation In AD (THC-AD), Johns Hopkins School of Medicine, United States

10:00 - 10:07 a.m. Jennifer Gatchel, Anxiety, Subjective Cognitive Decline, and Cortical Amyloid in Preclinical Autosomal Dominant Alzheimer's Disease: A Preliminary Report, Harvard Medical School, United States

10:07 - 10:14 a.m. Moyra Mortby, Mild Behavioral Impairment: What Are the Risk Factors?, Australian National University, Australia

10:14 - 10:21 a.m. Suzanne Hendrix, Optimizing Measurement Of Agitation And Aggression In Dementia, Pentara Corporation, United States

10:21 - 10:28 a.m. Joseph Kass, Predictors Of Atypical Antipsychotic Treatment In An AD Clinical Population, University of Texas, United States

10:28 - 10:30 a.m. Joanne Bell, Closing Remarks, Inc Research, United States


10:30 a.m. Noon

Reserve, Resilience and Protective Factors PIA
ExCeL London (Platinum Suite 2)
Scientific Session: 10:30 a.m. – 12:30 p.m. | See Tuesday for Business Meeting schedule.

Research on reserve, resilience and protective factors in Alzheimer's disease (AD) has received growing attention, driven by the repeated finding that higher levels of life experiences such as cognitive, social and physical activities are associated with both reduced risk and delayed onset of dementia. The Reserve, Resilience and Protective Factors PIA focuses on epidemiologic, clinical/neuropsychological and neuroimaging/biomarker approaches to understanding reserve and resilience. The PIA will also explore intervention strategies that target mechanisms underlying reserve or resilience in order to promote individual brain health and prevent or delay the onset of dementia. Our objectives include: 1) Establish a collaborative forum and network to foster knowledge and research on the mechanisms that may promote reserve and resilience and help prevent or delay cognitive aging and Alzheimer's disease. 2) Develop consensus guidelines on research criteria for studying brain reserve and resilience, and propose strategies to investigate the different underlying brain mechanisms (neuroprotective or compensatory). 3) Promote collaborative projects on the topic, including joint prospective neuroimaging studies, joint grant applications and merging data sets collected by PIA members. Following up on our extremely successful inaugural session last year, we will once again have a data blitz that will allow multiple investigators to share their work. This year each presenter will have a bit more time, and we will allow time for questions.

Agenda

10:30 - 10:35 a.m. Yaakov Stern, Introduction to the Data Blitz, Columbia University, United States

Differential Effects Of Early-, Mid- And Late-life Experiences On Reserve And Resilience

10:42 - 10:49 a.m. Eider M. Arenaza-Urquijo, Differential Effects Of Early And Late-Life Experiences On Amyloid Deposition Versus Neurodegeneration, INSERM, France

10:49 - 10:56 a.m. Roger T. Staff, Early Life Intelligence, Social Class And Education And Its Association With Memory And The Trajectory Of Decline In Late Life, NHS Grampian, United Kingdom

10:56 - 11:03 a.m. William S. Kremen, Childhood Ses, Cognitive Reserve, Adult Ses And Cognitive Activities: Impact On Later Life Cognitive Outcomes, University of California, United States

Risk and Protective Factors

11:03 - 11:10 a.m. Katerina Sheardova, The Effect Of Spirituality/Religiosity On Regional Brain Atrophy In Subjects At Risk Of Alzheimer’s Disease, St. Anne’s University Hospital, Czech Republic

11:10 - 11:17 a.m. Stephanie A. Schultz, The Association Between Personality And Tau Pet Deposition In Cognitively Normal Older Adults, Wisconsin Alzheimer's Disease Research Center and William S. Middleton Memorial VA Hospital, United States

11:17 - 11:24 a.m. Catherine M. Roe, Impact Of Cognitive Reserve And Preclinical Ad On Longitudinal Driving Performance, Knight Alzheimer's Disease Research Center, Washington University School of Medicine, United States

Risk Prediction and Heritability Of Reserve And Resilience

11:24 - 11:31 a.m. Anita C. Van Loenhoud, Predicting Progression In Pre-dementia Stages Of Alzheimer’s Disease With A Neuroimaging Measure Of Cognitive Reserve, VU University Medical Center, Amsterdam

11:31 - 11:38 a.m. Simon Law, Genetic Risk Profile For Prediction Of Cognitive Decline In Pre-symptomatic Alzheimer’s Disease, Centre of Excellence for Alzheimer's Disease Research and Care, Australia

11:38 - 11:45 a.m. Timothy Hohman, Heritability Of Asymptomatic Alzheimer’s, Disease, Centre of Excellence for Alzheimer's Disease Research and Care, United States

11:45 - 11:52 a.m. Roger Dixon, Discriminating And Predicting Cognitive Exceptionality And Resilience: A Roadmap For Trajectory And Interaction Analyses With Risk And Protective Factors, University of Alberta, Canada

11:52 - 11:59 a.m. Prashanthi Vemuri, Investigating Protective Factors For Amyloid And AD Pattern Neurodegeneration To Discover Paths To "Exceptional Aging" Without AD, Mayo Clinic, Rochester, United States

Functional Brain Mechanisms Of Reserve And Resilience

11:59 a.m. - 12:06 p.m. Nikolai Franzmeier, Cross-network Coupling Of The Fronto-parietal Control Network During Memory Performance Supports Protective Effects Of Education In Aging, Klinikum der Universität München, Ludwig-Maximilians-University LMU, Germany

12:06 - 12:13 p.m. Elisa de Paula Franca Resende, Education Can Strengthen The Role Of The Left Hippocampus In Episodic Memory Performance, Federal University of Minas Gerais, Brazil

11:40 - 11:45 a.m. Lidia Vaqué-Alcázar, Working Memory And Brain Maintenance: A Longitudinal Study, University of Barcelona, Spain

12:13 - 12:20 p.m. Gabriel Laliberte-Ducharme, Associated With Early And Lifelong Cognitively Stimulating Activities Moderates Working Memory Differences In Normal Aging, Université de Montréal, Canada

12:20 - 12:27 p.m. Jie Zhang, Beta-amyloid Accumulation Hurts And Crystallized Knowledge Helps Brain Modulatory Capacity, University of Texas at Dallas, United States

12:27 - 12:30 p.m. Yaakov Stern, Closing Remarks, Columbia University, United States


Subjective Cognitive Decline PIA
ExCeL London (Platinum Suite 1)
Scientific Session: 10:30 a.m. – Noon | See Monday for Business Meeting schedule.

This year's scientific meeting of the Subjective Cognitive Decline (SCD) PIA will have a program with a highly interactive nature. Seven – most junior – presenters will provide results and updates on exciting new studies, covering a range of topics. Topics include optimal methods for case finding, relationship between subjective and objective cognitive decline, functional brain connectivity, amyloid and tau imaging. We expect that there will be ample time for discussion of results and fostering new ideas for collaboration.

Agenda

10:30 - 10:35 a.m. Frank Jessen, Opening Remarks, University of Cologne, Germany

10:35 - 10:45 a.m. Argonde van Harten, Defining SCD To Provide Optimal Case Finding: A Focus On Methodology, Mayo Clinic, United States

10:45 - 10:55 a.m. Matthew Baumgart, The Correlation Between Subjective Cognitive Decline And Performance On Cognitive Assessment Tests: Results From A Population-based Study, Alzheimer’s Association, United States

10:55 - 11:05 a.m. Lisa Miebach, Qualitative Assessment Of Subjective Cognitive Decline: Interpretative Phenomenological Analysis Of Interviews With Memory Clinic Patients, University of Bonn, Germany

11:05 - 11:15 a.m. Rachel Buckley, How Well Does A Single Binary Question About Subjective Cognitive Decline Identify The Presence Of High Global A? Cross-cohort Study With AIBL, ADNI And HABS, Harvard Medical School, United States

11:15 - 11:25 a.m. Sander Verfaillie, Subjective Cognitive Decline Is Associated With Altered Posterior Cingulate Connectivity In Elderly With A Familial History Of Alzheimer's Disease, VU University Medical Center, Amsterdam

11:25 - 11:35 a.m. Ying Han, Intrinsic Brain Networks Of Cognitive Components In Subjective Cognitive Decline, Beijing Institute For Brain Disorders, China

11:25 - 11:35 a.m. Ying Han, Intrinsic Brain Networks Of Cognitive Components In Subjective Cognitive Decline , Beijing Institute For Brain Disorders, China

11:35 - 11:45 a.m. Tessa Timmers, [18f]AV1451 Binding Potential In Relation To Amyloid Status And Cognition In Subjects With Subjective Cognitive Decline , VU University Medical Center, Amsterdam

11:45 a.m. - 12:00 p.m Frank Jessen, Discussion, University of Cologne, Germany


11 a.m. – 1:30 p.m.

Down Syndrome and Alzheimer's Disease PIA
ExCeL London (Platinum Suite 3)
Business Meeting: 11 a.m. – Noon | Scientific Session: Noon – 1:30 p.m.

Individuals with Down syndrome, characterized by a triplication of chromosome 21, consistently develop Alzheimer's pathology in middle age, yet there is delay in dementia onset, and a high variability in this delay. The Down Syndrome and Alzheimer's Disease PIA will highlight new, translational research from leaders in the Down syndrome field. We will follow the formal presentations from established investigators with a "data blitz," consisting of short presentations from trainees in the Down syndrome field.

Agenda

12 - 12:05 p.m. Donna Wilcock, Opening Remarks, Denver University, United States

12:05 - 12:25 p.m. William Mobley, University of California San Diego, United States

12:25 - 12:45 p.m. Anne-Sophie Rebillat, Jerome Lejeune Institute, France

12:45 - 1:05 p.m. Andre Strydom, University College London, United Kingdom

1:05 - 1:20 p.m. Data Blitz Featuring Young Investigators: Alex Helman, University of Kentucky, United States, Victor Montal, Hospital de la Santa Creu, Barcelona, Lisi Flores Aguilar, McGill University, Canada

1:20 - 1:25 p.m. Group Discussion

1:25 - 1:30 p.m. Closing Remarks


Biofluid Based Biomarkers PIA
ExCeL London (Platinum Suite 4)
Business Meeting: 11 a.m. – Noon | Scientific Session: Noon – 1:30 p.m.

There will be three main areas of focus for the Biofluid-Based Biomarkers PIA Day session. First, updates to the PIA and an overview of the Global Biomarker Standardization Consortium (GBSC) will be provided. Second, four students will present brief presentations of their work related to biofluids and neurodegenerative diseases. Third, speakers and a panel discussion will take place on the best context of use for cerebrospinal fluid (CSF), blood and other biofluid biomarkers for Alzheimer's disease and other dementias.

Agenda

Noon - 12:10 p.m. Sid O'Bryant, PIA Update, University of North Texas Health Science Center, United States

12:10 - 12:20 p.m. Charlotte Tuenissen, GBSC Overview, VU University Medical Center, Netherlands

12:20 - 12:25 p.m. Nicholas Ashton, A Mass Spectrometry-based Discovery And Replication Of A Multi-analyte Classifier For Neocortical Amyloid Pathology, King’s College London, United Kingdom

12:25 - 12:30 p.m. Francisca A. de Leeuw, Profiling Peripheral Metabolic Dysregulation In Alzheimer’s Disease: The Added Value Of Multiple Signatures, VU University Medical Center, Netherlands

12:30 - 12:35 p.m. Inger van Steenoven, Alpha-synuclein Species As Potential CSF Biomarkers For Dementia With Lewy Bodies, VU University Medical Center, Netherlands

12:35 - 12:40 p.m. To be announced.

12:40 - 12:50 p.m. Ulf Andreasson, Context Of Use -- CSF Pros/Cons, University of Gothenberg, Sweden

12:50 - 1 p.m. Andreas Jeromin, Context Of Use - Plasma Pros/Cons , Quanterix, United States

1 - 1:10 p.m. Henrik Zetterberg, Other Fluids - Pros/Cons, University of Gothenberg, Sweden

1:10 - 1:25 p.m. Panel Discussion

1:25 - 1:30 p.m. Michelle Mielke, Closing Remarks, Mayo Clinic, United States


1 – 3:30 p.m.

Electrophysiology PIA
ExCeL London (Platinum Suite 1)
Scientific Session: 1 – 2:30 p.m. | Business Meeting: 2:30 – 3:30 p.m.

Electrophysiological methods have provided important insights into the way the brain processes information, from single neurons to large-scale brain networks. This broad span of methods has contributed to our understanding of how Alzheimer's disease (AD) affects brain activity. Electrophysiological methods provide a crucial bridge between cellular processes, neuronal network activity, cognition and functional neurodegeneration with a great potential for synergistic use with other diagnostic methods for early detection of neurodegenerative symptoms. With non-evasive EEG/ERP technology becoming widely accessible, the technology can accommodate the realities of patient care as well as industry needs. Its high temporal advantages can be applied with scientific rigor, while also MEG studies have been systematically addressing the functional alterations seen in MCI as well as in AD patients. Furthermore, electrophysiological methods deliver considerable promise as translatable biomarkers in both preclinical and clinical applications, offering a translational window on brain processes altered by neurodegeneration as well as means of stratifying patients in clinical studies. Consequently, they are also gaining an established and valuable role in Alzheimer drug discovery and development research in pharmaceutical industry. The Electrophysiology PIA (EPIA) aims to provide a forum for education through symposia and lectures, a platform for networking and exchange with members who share subspecialties, and support for junior scientists and other researchers to learn about the latest developments in the field. The PIA Day session includes a dedicated symposium with a selection of excellent speakers, each discussing their own experience in one of the areas within the wide span from preclinical to clinical and from academic to scientific applications in AD research.

Agenda

1 - 1:20 p.m. Wilhelmus (Pim) Drinkenburg, Neurophysiological Assessment Of Neural Network Plasticity And Connectivity In A Tau Preclinical Mouse Model Of Alzheimer's Disease, Janssen, Belgium

1:20 - 1:40 p.m. Claudio Babiloni, Resting EEG And Auditory ERP Markers Can Be Back-translated From Prodromal Alzheimer's Disease Patients To Healthy Young Volunteers Under A Cognitive Challenge, University of Rome, Italy

1:40 - 2 p.m. Kristinn Johnsen, Biomarkers Derived From Resting State EEG Data In Patients With Alzheimer's Disease: Classification, Prediction, And Monitoring, Mentis Cura, Ireland

2 - 2:20 p.m. Laura Bonanni, Multimodal EEG And Neuroimaging Biomarkers Of Alzheimer's And Lewy Body Diseases, Università degli Studi G. d'Annunzio Chieti e Pescara, Italy

2:20 - 2:30 p.m. Discussion


Non-pharmacological Interventions PIA
ExCeL London (Platinum Suite 2)
Scientific Session: 1 – 2:30 p.m. | Business Meeting: 2:30 – 3:30 p.m.

A biopsychosocial framework of dementia emphasizes that overall functioning cannot be solely explained by underlying brain pathology, and there is evidence that certain barriers to activity and participation can be removed through effective non-pharmacological interventions, and that the experience of the person with dementia and their families can be improved through appropriate management of personal, social and environmental factors. In addition, psychosocial, lifestyle and environmental factors may impact on risk of developing dementia, and interventions in these areas can contribute to risk reduction. The scientific session of the Non-Pharmacological Interventions PIA, held on Saturday, July 15 as part of PIA Day, will be an opportunity to learn about the latest progress in non-pharmacological interventions, including but not limited to, cognition and function-oriented treatments, physical activity and dietary interventions targeting older adults with dementia or at risk of dementia. We are delighted to announce that three leading researchers, Gaël Chételat, Ph.D., Benjamin Hampstead, Ph.D., and Sylvie Belleville, Ph.D., have accepted our invitation to give keynote presentations during this session and to present their research. The program will also include a Data Blitz session, in which six additional PIA members will present brief 5-minute updates on their research. The Executive Committee looks forward to seeing you at the Non-pharmacological Interventions PIA Day Scientific Session.

Agenda

1 - 1:10 p.m. Alex Bahar-Fuchs, Introduction And Opening Remarks, Health, and Wellbeing Research School of Population Health ANU College of Medicine, Australia

1:10 - 1:25 p.m. Benjamin M. Hampstead, The Current State Of, And Future Directions For, Non-invasive Brain Stimulation In Dementia, University of Michigan, United States

1:25 - 1:40 p.m. Gaël Chételat, The Silver Santē Study: A European Project On Meditation And English Learning In Asymptomatic Older Adults At-risk For Alzheimer's Disease, Cyceron, INSERM – French Institute for Biomedical Research, France

1:40 - 1:45 p.m. Nicolas Cherbuin, Physical Activity Interventions In Relation To Cognition In Older Adults, Australian National University, Australia

1:45 - 1:50 p.m. Roos Jutten, Quality Aspects Of A Novel Cognitive-functional Composite To Detect Clinically Relevant Changes In Mild Alzheimer's Disease: Feasibility, Test-retest Reliability And Practice Effects, Alzheimer’s Center, VU University Medical Center, Netherlands

1:50 - 1:55 p.m. Aleksandra Kudlicka, GREAT Trial: Personalised Cognitive Rehabilitation Goals Of People With Early Stage Dementia, University of Exeter, England

1:55 - 2 p.m. Amit Lampit, Design Of Controls In Trials Of Computerised Cognitive Training Is Ineffectual: A Meta-analysis In Healthy Older Adults, University of Sydney, Australia

2 - 2:05 p.m. Joseph Lee, Does Physical Activity Protect Against Memory Decline In Individuals With High Genetic Risk? A Study Of Carriers Of The Psen1-g206a Mutation Or Apoe APOE4 Allele, Columbia University, United States

2:05 - 2:10 p.m. Linda Wesselman, Improving Brain Health Through An Online Lifestyle Program: Preferences Of Individuals With Subjective Cognitive Decline, VU University Medical Center, Netherlands

2:10 - 2:25 p.m. Sylvie Belleville, Using Cognitive Training And Engaging Leisure Activities To Promote Cognitive Reserve In Older Adults At Risk Of Dementia, University of Montréal, Canada

2:25 - 2:30 p.m. Yi Tang, Closing Remarks, Xuanwu Hospital, Capital Medical University, China

CIDER Workgroup Meeting (NPI PIA)
ExCeL London, South Gallery 25-26
4 – 5:30 p.m.


2:30 – 5:30 p.m.

Perioperative Cognition PIA
ExCeL London (Platinum Suite 4)
Scientific Session: 2:30 – 4 p.m. | Business Meeting: 4:30 – 5:30 p.m.

The Perioperative Cognition PIA is a group of investigators who are concerned about cognitive outcomes in our older population of patients who undergo anesthesia and surgery. Our multidisciplinary approach to the study of postoperative cognitive disorders has the long-range goal of modulating what we do in the perioperative period to improve postoperative cognitive outcomes including delirium, and help our patients make informed choices. Our most recent collaborative work includes the International Nomenclature Consensus Work Group, which has led an effort to revise the nomenclature for what had been loosely termed, "Postoperative Cognitive Dysfunction" or POCD. We have active collaborations with other investigators from the Alzheimer's disease research field, and welcome anyone who is interested in this exciting field of investigation.

Agenda

2:30 - 2:35 p.m. Update On the Perioperative Cognition PIA
Lisbeth Evered, St. Vincent's Hospital, Australia
Esther Oh, Johns Hopkins University, United States

2:35 - 2:51 p.m. Huafeng Wei, Mechanisms of General Anesthetics Mediated Neurodegeneration in Alzheimer's Disease, University of Pennsylvania, United States

2:51 - 3:07 p.m. Lisabeth Evered, Does Frailty Predict Cognitive Decline Following Non-cardiac Surgery?, University of Melbourne, Australia

3:07 - 3:23 p.m. Joanne Hardwick, Delirium and Dementia in the Perioperative, Royal Free Hospital, London

3:23 - 3:39 p.m. Emma Cunningham, CSF AB Predicts Postoperative Delirium in Elderly Elective Orthopaedic Population, Queens University, Belfast, United Kingdom

3:39 - 3:55 p.m. Richard Jones, The Association of Post-operative Cognitive Decline and reserve Delirium, Brown University, United States

3:55 - 4 p.m. Esther Oh, Closing Remarks, Johns Hopkins University, United States


Vascular Cognitive Disorders PIA
ExCeL London (Platinum Suite 3)
Scientific Session: 2:30 – 4 p.m. | Business Meeting: 4:30 – 5:30 p.m.

White Matter Lesions - Culprit or Bystander in Dementia?
White matter lesions are frequently seen on brain MRI scans of older people. They are interpreted as cerebral small vessel disease, the most common cause of vascular cognitive impairment. In this Vascular Disorders PIA scientific session we will explore current understanding of white matter lesions and their role in cognitive impairment and dementia. Expert presentations will cover:
• State of the art MRI findings (Susanne Van Veluw, MGH and Utrecht)
• Data from large experimental species (Doug Rosene, Boston University)
• Neuropathology from large cohorts (Julie Schneider, Rush Medical Center)
Small-group breakout sessions will follow, each led by a senior researcher and scribed by a junior researcher. The Vascular Disorders PIA has new leadership. The new team are Deb Gustafson (United States, Chair), Atticus Hainsworth (United Kingdom), Geert-Jan Biessels (Netherlands) and Adam Brickman (United States). We aim to connect the global VCI community. We particularly want to engage our junior and early career colleagues.

Agenda

2:30 - 2:32 p.m. Deb Gustafson, Welcome, State University of New York, United States

2:32 - 2:37 p.m. Rod Corriveau, The VCID Concept, NINDS, United States

2:37 - 2:52 p.m. Susanne Van Veluw, What Do The MRI Signals Mean? The 7 Tesla Experience, Massachusetts General Hospital, United States

2:52 - 3:07 p.m. Doug Rosene, White Matter Pathology And Cognitive Impact In The Aging Non-human Primate, Boston University, United States

3:07 - 3:22 p.m. Julie A Schneider, Which White Matter Hyperintensities Are Relevant To Vascular Cognitive Impairment?, Rush Medical Center, United States

3:22 - 3:47 p.m. Breakout session

3:47 - 4 p.m. Atticus H Hainsworth, Closing Remarks, St. George’s University of London, United Kingdom


4 – 5:30 p.m.

Atypical Alzheimer's Disease and Associated Syndromes PIA
ExCeL London (Platinum Suite 2)
Scientific Session: 4 – 5:30 p.m. | See Wednesday for Business Meeting schedule.

The Atypical Alzheimer's disease and Associated Syndromes PIA is an international community of investigators interested in studying unconventional aspects of Alzheimer’s disease (AD). We provide a forum to discuss what defines atypical and typical AD in order to reveal common misconceptions that may impact patient care, influence animal models and interfere with biomarker interpretation. Our multi-disciplinary membership is made up of both clinicians and scientists to facilitate a well-rounded approach to investigating atypical AD clinical phenotypes (e.g. posterior cortical atrophy), young onset AD, neuroimaging patterns (e.g. structural MRI, tau PET) and underlying neuropathologic phenotypes. Our collaborative efforts have recently been exampled by the published “Consensus classification of posterior cortical atrophy.”

Agenda

4 - 4:10 p.m.Melissa E. Murray, Opening Remarks, Mayo Clinic, United States

4:10 - 4:20 p.m. Baayla Boon, Non-amnestic Alzheimer’s Disease: A Possible Role For Neuroinflammation?, VU Medical Center, Netherlands

4:20 - 4:30 p.m. Mari-Nilva Maia da Silva, Progression Of Visual Fields In Posterior Cortical Atrophy Mirrors That Of Cognitive Deficits, University College London, United Kingdom

4:30 - 4:40 p.m. Paul K. Crane, Psychometrically-defined Late-onset Alzheimer’s Disease (Load) Subgroups In 5 Studies (Total N = 4,170): Prevalence At First Visit, Associations With APOE Genotype And IGAP, SNPs, And GWAS, University of Washington, United States

4:40 - 4:50 p.m. Fulvio Da Re, Amnestic And Non-Amnestic Phenotypes Of Alzheimer's Disease: An MRI-based Phasing Analysis, University of Pennsylvania, United States

4:50 - 5:00 p.m. Stephanie Vos, Characterization Of Suspected Non-Alzheimer’s Disease Pathophysiology (SNAP) In Individuals With Mild Cognitive Impairment Using Neuroimaging, Maastricht University Medical Centre, Netherlands

5:00 - 5:10 p.m. Sebastian J. Crutch, Longitudinal Evaluation Of Neuropsychological And Neuroimaging Progression In Posterior Cortical Atrophy, University College London, United Kingdom

5:10 - 5:30 p.m. Melissa E. Murray, Closing Remarks, Mayo Clinic, United States


Design and Data Analytics PIA
ExCeL London (Platinum Suite 1)
Scientific Session: 4 – 5:30 p.m. | See Tuesday for Business Meeting schedule.

The purpose of the Design and Data Analytics (DaDA) PIA is to highlight critical data and analysis needs and to facilitate development and application of best methods for advancing research on dementia and related disorders. Our annual scientific session features presentations on statistical analysis for identifying individuals exhibiting different patterns of change using electronic health record data, methods for statistical treatment of missing data due to death in longitudinal studies and models for practice effects in analysis of cognitive change.

Agenda

4 - 4:10 p.m. Graciela Muniz, Opening Remarks And Introductions, University of Edinburgh, United Kingdom

4:10 - 4:30 p.m. Elizabeth Baker, Dementia Sub-group And Trajectory Profiling In UK Mental Health Records, King’s College London, United Kingdom

4:30 - 4:50 p.m. Lan Wen, Statistical Methods For Dealing With Missing Data Due To Death In Longitudinal Studies Of Ageing, MRC Biostatistics Unit, United Kingdom

4:50 - 5:10 p.m. Melinda Power, Jump, Hop, Or Skip: Modeling Practice Effects In Studies Of Determinants Of Cognitive Change In Older Adults, George Washington University, United States

5:10 - 5:30 p.m. Scott Hofer, Closing Remarks, Oregon Health & Science University, United States

PIA Business Meeting

Subjective Cognitive Decline PIA
Novotel Hotel, Room: London II
Business Meeting: 7 – 8 a.m.



PIA Business Meetings

Design and Data Analytics PIA
Novotel Hotel, Room: London II
Business Meeting: 12 – 1 p.m.


Reserve, Resilience and Protective Factors PIA
Crowne Plaza Hotel, Room: Tower Business Meeting: 6 – 7 p.m.



PIA Business Meetings

Atypical Alzheimer's Disease and Associated Syndromes PIA
Novotel Hotel, Room: London II
Business Meeting: 7 – 8 a.m.


Diversity and Disparities PIA
Crowne Plaza Hotel, Room: Tower
Business Meeting: 7 – 8 a.m.


Alliance of Women Alzheimer's Researchers PIA
Novotel Hotel, Room: London II
Business Meeting: 6 – 7 p.m.






Join the Conversation #AAIC17

Follow

Exhibitors

Exhibitors

Sponsors

Sponsorship

> 1200px
lg
> 992px
md
> 768px
sm
< 767px
xs